RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for securities fraud, alleging that the company misled investors regarding the efficacy of its drug setrusumab in clinical trials [1] Group 1: Lawsuit Details - The lawsuit covers purchasers of Ultragenyx common stock from August 3, 2023, to December 26, 2025, and claims that the company provided misleading information about the expected results of its Phase III Orbit and Cosmic Studies [1] - Defendants allegedly made positive statements about setrusumab's ability to reduce annualized fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts about the drug's true potential [1] - The lawsuit asserts that these misleading statements led to Ultragenyx securities being purchased at artificially inflated prices, resulting in investor damages when the truth was revealed [1] Group 2: Legal Representation - Investors wishing to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [1] - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and encourages selecting qualified counsel with a proven track record [1] - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 alone [1]